Hybrigenics S.A.

As of December 31, 2023, Hybrigenics S.A. has 383.15M shares outstanding.

These figures are as of December 31, 2023. The price-to-sales ratio is 22.16, and the price-to-book ratio stands at -0.51.

These figures are as of December 31, 2023. The EV/Sales ratio of 30.60 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Hybrigenics S.A. trades at an EV/FCF ratio of 88.30, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2023, Hybrigenics S.A. maintains a current ratio of 0.18, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -69.10, indicating conservative leverage, while an interest coverage ratio of -102.50 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2023. Return on assets (ROA) is negative at -232.20, reflecting losses generated across the asset base.

As of the close on July 16, 2024, Hybrigenics S.A.'s stock has declined approximately 80.00% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.02.

Over the twelve months ended December 31, 2023, Hybrigenics S.A. posted a gross margin of -38.14, reflecting its pricing power and cost economics. The operating margin of -3,551.75 and net profit margin of -4,910.49 provide insight into operational efficiency.

Hybrigenics S.A.'s most recent stock split took place on July 4, 2017 with a 1000:1033 split ratio.

As of December 31, 2023, Hybrigenics S.A. has an Altman Z-Score of -111.57, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.